Key Takeaways
- Lexicon is squarely focused on a Phase IIb data readout for pilavapadin, or LX9211, for diabetic peripheral neuropathic pain (DPNP), coming in the first quarter.
Lexicon Pharmaceuticals has an important data readout coming in the first quarter for a Phase IIb study testing pilavapadin, or...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?